Latest Conference Articles

Sagar Lonial, MD, FACP, FASCO, discusses MRD-negativity data with iberdomide plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses Project Optimus dose selection and MRD as an early end point in the phase 3 EXCALIBER-RRMM trial.

Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.

Dirk van Esser, MD, discusses safety with KRd in the EMN15/HOVON147 trial and how to select patients with high-risk smoldering myeloma for treatment.

Dirk van Esser, MD, discusses long-term EMN15/HOVON147 data for KRd vs Rd in high-risk smoldering multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses preclinical data on an AI-designed BCMA/FcRL5 trispecific antibody in multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses the design and antigen-independent activity of a BCMA/FcRL5 trispecific antibody in multiple myeloma.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across 2 cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

Ja Min Byun, MD, PhD, discusses response consistency and the future of mezigdomide plus elranatamab in multiple myeloma.

Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Brad S. Kahl, MD, discusses how the TRIANGLE trial supports frontline therapy without autologous transplantation in mantle cell lymphoma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.

The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.

William N. William Jr, MD, discusses the design, toxicity lessons, and TP53 co-mutant signal from the phase 2 AMIGO-1 trial of amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.

Julia K. Rotow, MD, discusses why dual EGFR inhibition prevented acquired resistance mutations but did not extend PFS, and where the combination fits now.

Laura Alder, MD, discusses a retrospective analysis in which early-morning tarlatamab infusions during cycle 1 did not improve outcomes in small cell lung cancer, and what a prospective test would require.

Laura Alder, MD, discusses a multi-institutional real-world analysis of local consolidation and continued tarlatamab in patients with oligoprogressive small cell lung cancer.

Julia K. Rotow, MD, discusses how T-DXd, zongertinib, and sevabertinib may be sequenced in first-line HER2-mutant NSCLC and why resistance profiling at progression matters.

Julia K. Rotow, MD, discusses subgroup results and post-progression treatment imbalances in the phase 3 DESTINY-Lung04 trial of first-line T-DXd in HER2-mutant NSCLC.

Yuanyuan Zhao, MD, discusses phase 1b data for the PD-1/VEGF bispecific RC148 (ABBV-1480) plus chemotherapy in first-line NSCLC, how it is engineered differently from ivonescimab and pumitamig, and what the global phase 3 program needs to show.

Osimertinib plus platinum-pemetrexed showed a numerical PFS and OS advantage over osimertinib alone regardless of baseline TP53 status in FLAURA2.

Alexander Drilon, MD, discusses future directions for zidesamtinib in TKI-naive, ROS1-positive NSCLC following the ARROS-1 trial.

Alexander Drilon, MD, discusses phase 1/2 ARROS-1 efficacy and safety findings with zidesamtinib in TKI-naive, ROS1-positive NSCLC.

Jay M. Lee, MD, discusses how NAUTIKA1 compares with ALNEO and LORIN, why full genomic profiling is now essential before starting chemoimmunotherapy, and how tumor boards will manage early-stage NSCLC in 5 years.

Jay M. Lee, MD, discusses the primary analysis of the ALK+ cohort of NAUTIKA1, what MPR status adds to risk stratification, and whether neoadjuvant alectinib is ready for patients today.